Eric Swayze, an executive at Ionis Pharmaceuticals, has disclosed several stock transactions in a recent SEC filing. These transactions are significant as they provide insight into the management of executive stock holdings within the pharmaceutical industry.
Background
Ionis Pharmaceuticals, Inc., a company based in Carlsbad, California, operates in the pharmaceutical preparations sector. The company, which was formerly known as Isis Pharmaceuticals, Inc., is known for its focus on developing innovative therapies for various diseases. The recent filing was made on October 19, 2026, and is part of a series of transactions reported by Swayze.
What the Filing Says
In the SEC filing, Swayze reported two key transactions involving Ionis common stock. On October 15, 2026, he acquired 125 shares through the vesting of Restricted Stock Units (RSUs). The filing states, "Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award." Additionally, on October 16, 2026, he sold 53 shares at a price of $43.5389 per share, which was noted as an automatic sale to cover tax withholding obligations.
Impact
These transactions may affect various stakeholders, including investors, employees, and competitors within the pharmaceutical industry. By managing his stock holdings actively, Swayze may influence perceptions of Ionis Pharmaceuticals' leadership and its commitment to shareholder value. Additionally, the nature of these transactions reflects ongoing trends in executive compensation and stock management practices.
What's Next
The filing does not say what happens next.